- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02997228
Chimiothérapie combinée, bevacizumab et/ou atezolizumab dans le traitement des patients atteints d'un cancer colorectal métastatique avec réparation des mésappariements d'ADN déficient, l'étude COMMIT
Étude d'immunothérapie dMMR/MSI-H métastatique du cancer colorectal (COMMIT) : une étude randomisée de phase III comparant l'association mFOLFOX6/bevacizumab/atezolizumab à l'agent unique atezolizumab dans le traitement de première ligne des patients présentant un défaut de réparation des mésappariements d'ADN (dMMR)/microsatellite Cancer colorectal métastatique à instabilité élevée (MSI-H)
This phase III trial studies how well combination chemotherapy, bevacizumab, and/or atezolizumab work in treating patients with deficient deoxyribonucleic acid (DNA) mismatch repair colorectal cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Chemotherapy drugs, such as fluorouracil, oxaliplatin, and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of the tumor. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving combination chemotherapy, bevacizumab, and atezolizumab may work better in treating patients with colorectal cancer.
Aperçu de l'étude
Statut
Intervention / Traitement
- Autre: Quality-of-Life Assessment
- Biologique: Bevacizumab
- Médicament: Fluorouracil
- Procédure: Magnetic Resonance Imaging
- Autre: Questionnaire Administration
- Procédure: Biospecimen Collection
- Médicament: Atezolizumab
- Médicament: Oxaliplatin
- Procédure: Computed Tomography
- Médicament: Leucovorin
- Procédure: Positron Emission Tomography
Description détaillée
PRIMARY OBJECTIVE:
I. To determine the efficacy, based on progression-free survival (PFS), of fluorouracil, oxaliplatin, and leucovorin calcium (modified [m]FOLFOX6)/bevacizumab plus atezolizumab (combination) as compared to single agent atezolizumab.
SECONDARY OBJECTIVES:
I. To compare the overall survival. II. To compare the objective response rates (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
III. To determine the safety profiles of single agent atezolizumab and the combination of mFOLFOX6/bevacizumab/atezolizumab in patients with mismatch-repair deficient (dMMR)/microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC).
IV. To determine the duration of response. V. To determine the duration of stable disease. VI. To determine the rate of progression-free survival (PFS) at 12 months. VII. To evaluate the disease control rate (complete response [CR] + partial response [PR] + stable disease [SD]) at 12 months.
TRANSLATIONAL OBJECTIVE:
I. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I (CLOSED TO ACCRUAL 6/4/2020): Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo computed tomography (CT) with or without positron emission tomography (PET) or magnetic resonance imaging (MRI) throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM II: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
ARM III: Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial.
After completion of study treatment, patients are followed up every 8 weeks for 18 months, and then every 12 weeks for up to 5 years.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Lieux d'étude
-
-
Arizona
-
Kingman, Arizona, États-Unis, 86401
- Kingman Regional Medical Center
-
-
Arkansas
-
Jonesboro, Arkansas, États-Unis, 72401
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro
-
-
California
-
Anaheim, California, États-Unis, 92806
- Kaiser Permanente-Anaheim
-
Baldwin Park, California, États-Unis, 91706
- Kaiser Permanente-Baldwin Park
-
Bellflower, California, États-Unis, 90706
- Kaiser Permanente-Bellflower
-
Berkeley, California, États-Unis, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Concord, California, États-Unis, 94520
- John Muir Medical Center-Concord
-
Fontana, California, États-Unis, 92335
- Kaiser Permanente-Fontana
-
Harbor City, California, États-Unis, 90710
- Kaiser Permanente South Bay
-
Irvine, California, États-Unis, 92618
- Kaiser Permanente-Irvine
-
Los Angeles, California, États-Unis, 90027
- Kaiser Permanente Los Angeles Medical Center
-
Los Angeles, California, États-Unis, 90034
- Kaiser Permanente West Los Angeles
-
Marysville, California, États-Unis, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, États-Unis, 95355
- Memorial Medical Center
-
Ontario, California, États-Unis, 91761
- Kaiser Permanente-Ontario
-
Orange, California, États-Unis, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
Orange, California, États-Unis, 92868
- Saint Joseph Hospital - Orange
-
Panorama City, California, États-Unis, 91402
- Kaiser Permanente - Panorama City
-
Riverside, California, États-Unis, 92505
- Kaiser Permanente-Riverside
-
Sacramento, California, États-Unis, 95816
- Sutter Medical Center Sacramento
-
Sacramento, California, États-Unis, 95817
- University of California Davis Comprehensive Cancer Center
-
Salinas, California, États-Unis, 93901
- Salinas Valley Memorial
-
San Diego, California, États-Unis, 92120
- Kaiser Permanente-San Diego Zion
-
San Diego, California, États-Unis, 92108
- Kaiser Permanente-Rio San Diego
-
San Marcos, California, États-Unis, 92078
- Kaiser Permanente-San Marcos
-
Walnut Creek, California, États-Unis, 94598
- John Muir Medical Center-Walnut Creek
-
Whittier, California, États-Unis, 90602
- Presbyterian Intercommunity Hospital
-
Woodland Hills, California, États-Unis, 91367
- Kaiser Permanente-Woodland Hills
-
-
Colorado
-
Aurora, Colorado, États-Unis, 80012
- Rocky Mountain Cancer Centers-Aurora
-
Aurora, Colorado, États-Unis, 80045
- UCHealth University of Colorado Hospital
-
Boulder, Colorado, États-Unis, 80303
- Boulder Community Foothills Hospital
-
Boulder, Colorado, États-Unis, 80304
- Rocky Mountain Cancer Centers-Boulder
-
Colorado Springs, Colorado, États-Unis, 80907
- Penrose-Saint Francis Healthcare
-
Colorado Springs, Colorado, États-Unis, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, États-Unis, 80920
- Memorial Hospital North
-
Denver, Colorado, États-Unis, 80218
- Rocky Mountain Cancer Centers-Midtown
-
Denver, Colorado, États-Unis, 80220
- Rocky Mountain Cancer Centers-Rose
-
Denver, Colorado, États-Unis, 80204
- Denver Health Medical Center
-
Denver, Colorado, États-Unis, 80206
- National Jewish Health-Main Campus
-
Denver, Colorado, États-Unis, 80218
- Saint Joseph Hospital - Cancer Centers of Colorado
-
Denver, Colorado, États-Unis, 80210
- AdventHealth Porter
-
Englewood, Colorado, États-Unis, 80113
- Mountain Blue Cancer Care Center - Swedish
-
Englewood, Colorado, États-Unis, 80113
- Swedish Medical Center
-
Fort Collins, Colorado, États-Unis, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, États-Unis, 80528
- Cancer Care and Hematology-Fort Collins
-
Golden, Colorado, États-Unis, 80401
- National Jewish Health-Western Hematology Oncology
-
Greeley, Colorado, États-Unis, 80631
- UCHealth Greeley Hospital
-
Greeley, Colorado, États-Unis, 80631
- Banner North Colorado Medical Center
-
Littleton, Colorado, États-Unis, 80120
- Rocky Mountain Cancer Centers-Littleton
-
Lone Tree, Colorado, États-Unis, 80124
- Rocky Mountain Cancer Centers-Sky Ridge
-
Loveland, Colorado, États-Unis, 80538
- Medical Center of the Rockies
-
Loveland, Colorado, États-Unis, 80539
- Banner North Colorado Medical Center - Loveland Campus
-
Thornton, Colorado, États-Unis, 80260
- National Jewish Health-Northern Hematology Oncology
-
Wheat Ridge, Colorado, États-Unis, 80401
- Intermountain Health Lutheran Hospital
-
-
Connecticut
-
Danbury, Connecticut, États-Unis, 06810
- Danbury Hospital
-
Hartford, Connecticut, États-Unis, 06102
- Hartford Hospital
-
Meriden, Connecticut, États-Unis, 06451
- Midstate Medical Center
-
New Britain, Connecticut, États-Unis, 06050
- The Hospital of Central Connecticut
-
Norwich, Connecticut, États-Unis, 06360
- William Backus Hospital
-
-
Delaware
-
Millville, Delaware, États-Unis, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, États-Unis, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, États-Unis, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, États-Unis, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, États-Unis, 20002
- Kaiser Permanente-Capitol Hill Medical Center
-
-
Florida
-
Fort Lauderdale, Florida, États-Unis, 33316
- Broward Health Medical Center
-
Fort Myers, Florida, États-Unis, 33905
- Regional Cancer Center-Lee Memorial Health System
-
Gainesville, Florida, États-Unis, 32610
- UF Health Cancer Institute - Gainesville
-
Jacksonville, Florida, États-Unis, 32207
- Baptist MD Anderson Cancer Center
-
Orlando, Florida, États-Unis, 32803
- AdventHealth Orlando
-
-
Georgia
-
Albany, Georgia, États-Unis, 31701
- Phoebe Putney Memorial Hospital
-
Athens, Georgia, États-Unis, 30607
- University Cancer and Blood Center LLC
-
Augusta, Georgia, États-Unis, 30912
- Augusta University Medical Center
-
Augusta, Georgia, États-Unis, 30901
- Augusta Oncology Associates PC-D'Antignac
-
Augusta, Georgia, États-Unis, 30909
- Augusta Oncology Associates PC-Wheeler
-
Newnan, Georgia, États-Unis, 30265
- CTCA at Southeastern Regional Medical Center
-
-
Idaho
-
Boise, Idaho, États-Unis, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
Boise, Idaho, États-Unis, 83712
- Saint Luke's Cancer Institute - Boise
-
Caldwell, Idaho, États-Unis, 83605
- Saint Alphonsus Cancer Care Center-Caldwell
-
Coeur d'Alene, Idaho, États-Unis, 83814
- Kootenai Health - Coeur d'Alene
-
Fruitland, Idaho, États-Unis, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, États-Unis, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, États-Unis, 83687
- Saint Alphonsus Cancer Care Center-Nampa
-
Nampa, Idaho, États-Unis, 83687
- Saint Luke's Cancer Institute - Nampa
-
Post Falls, Idaho, États-Unis, 83854
- Kootenai Clinic Cancer Services - Post Falls
-
Sandpoint, Idaho, États-Unis, 83864
- Kootenai Clinic Cancer Services - Sandpoint
-
Twin Falls, Idaho, États-Unis, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Bloomington, Illinois, États-Unis, 61704
- Illinois CancerCare-Bloomington
-
Canton, Illinois, États-Unis, 61520
- Illinois CancerCare-Canton
-
Carthage, Illinois, États-Unis, 62321
- Illinois CancerCare-Carthage
-
Centralia, Illinois, États-Unis, 62801
- Centralia Oncology Clinic
-
Chicago, Illinois, États-Unis, 60612
- University of Illinois
-
Chicago, Illinois, États-Unis, 60612
- Rush MD Anderson Cancer Center
-
Danville, Illinois, États-Unis, 61832
- Carle at The Riverfront
-
Decatur, Illinois, États-Unis, 62526
- Cancer Care Specialists of Illinois - Decatur
-
Dixon, Illinois, États-Unis, 61021
- Illinois CancerCare-Dixon
-
Effingham, Illinois, États-Unis, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, États-Unis, 62401
- Carle Physician Group-Effingham
-
Eureka, Illinois, États-Unis, 61530
- Illinois CancerCare-Eureka
-
Evanston, Illinois, États-Unis, 60201
- NorthShore University HealthSystem-Evanston Hospital
-
Galesburg, Illinois, États-Unis, 61401
- Illinois CancerCare-Galesburg
-
Glenview, Illinois, États-Unis, 60026
- NorthShore University HealthSystem-Glenbrook Hospital
-
Highland Park, Illinois, États-Unis, 60035
- NorthShore University HealthSystem-Highland Park Hospital
-
Kewanee, Illinois, États-Unis, 61443
- Illinois CancerCare-Kewanee Clinic
-
Macomb, Illinois, États-Unis, 61455
- Illinois CancerCare-Macomb
-
Mattoon, Illinois, États-Unis, 61938
- Carle Physician Group-Mattoon/Charleston
-
Maywood, Illinois, États-Unis, 60153
- Loyola University Medical Center
-
Mount Vernon, Illinois, États-Unis, 62864
- SSM Health Good Samaritan
-
O'Fallon, Illinois, États-Unis, 62269
- Cancer Care Center of O'Fallon
-
Ottawa, Illinois, États-Unis, 61350
- Illinois CancerCare-Ottawa Clinic
-
Pekin, Illinois, États-Unis, 61554
- Illinois CancerCare-Pekin
-
Peoria, Illinois, États-Unis, 61615
- Illinois CancerCare-Peoria
-
Peru, Illinois, États-Unis, 61354
- Illinois CancerCare-Peru
-
Princeton, Illinois, États-Unis, 61356
- Illinois CancerCare-Princeton
-
Springfield, Illinois, États-Unis, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, États-Unis, 62702
- Springfield Clinic
-
Urbana, Illinois, États-Unis, 61801
- Carle Cancer Center
-
Washington, Illinois, États-Unis, 61571
- Illinois CancerCare - Washington
-
-
Indiana
-
Indianapolis, Indiana, États-Unis, 46237
- Franciscan Health Indianapolis
-
Indianapolis, Indiana, États-Unis, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
Indianapolis, Indiana, États-Unis, 46219
- Community Cancer Center East
-
Indianapolis, Indiana, États-Unis, 46227
- Community Cancer Center South
-
Indianapolis, Indiana, États-Unis, 46256
- Community Cancer Center North
-
Kokomo, Indiana, États-Unis, 46904
- Community Howard Regional Health
-
Lafayette, Indiana, États-Unis, 47905
- Franciscan Saint Elizabeth Health - Lafayette East
-
Michigan City, Indiana, États-Unis, 46360
- Woodland Cancer Care Center
-
Mooresville, Indiana, États-Unis, 46158
- Franciscan Health Mooresville
-
Terre Haute, Indiana, États-Unis, 47804
- Union Hospital
-
-
Iowa
-
Ames, Iowa, États-Unis, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, États-Unis, 50010
- McFarland Clinic - Ames
-
Bettendorf, Iowa, États-Unis, 52722
- University of Iowa Healthcare Cancer Services Quad Cities
-
Boone, Iowa, États-Unis, 50036
- McFarland Clinic - Boone
-
Cedar Rapids, Iowa, États-Unis, 52403
- Mercy Hospital
-
Cedar Rapids, Iowa, États-Unis, 52403
- Oncology Associates at Mercy Medical Center
-
Clive, Iowa, États-Unis, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, États-Unis, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Des Moines, Iowa, États-Unis, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, États-Unis, 50314
- Broadlawns Medical Center
-
Des Moines, Iowa, États-Unis, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, États-Unis, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Fort Dodge, Iowa, États-Unis, 50501
- McFarland Clinic - Trinity Cancer Center
-
Fort Dodge, Iowa, États-Unis, 50501
- UI Healthcare Mission Cancer and Blood - Fort Dodge
-
Iowa City, Iowa, États-Unis, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
Jefferson, Iowa, États-Unis, 50129
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, États-Unis, 50158
- McFarland Clinic - Marshalltown
-
West Des Moines, Iowa, États-Unis, 50266
- Mercy Medical Center-West Lakes
-
-
Kansas
-
Hays, Kansas, États-Unis, 67601
- HaysMed
-
Lawrence, Kansas, États-Unis, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, États-Unis, 66061
- The University of Kansas Cancer Center - Olathe
-
Salina, Kansas, États-Unis, 67401
- Salina Regional Health Center
-
Topeka, Kansas, États-Unis, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, États-Unis, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
Wichita, Kansas, États-Unis, 67208
- Cancer Center of Kansas-Wichita Medical Arts Tower
-
Wichita, Kansas, États-Unis, 67214
- Cancer Center of Kansas - Wichita
-
-
Kentucky
-
Bardstown, Kentucky, États-Unis, 40004
- CommonSpirit Saint Joseph Hospital - Bardstown
-
Lexington, Kentucky, États-Unis, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, États-Unis, 40503
- Baptist Health Lexington
-
Lexington, Kentucky, États-Unis, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
Louisville, Kentucky, États-Unis, 40202
- Norton Hospital Pavilion and Medical Campus
-
Louisville, Kentucky, États-Unis, 40241
- Norton Brownsboro Hospital and Medical Campus
-
Louisville, Kentucky, États-Unis, 40217
- Norton Audubon Hospital and Medical Campus
-
-
Louisiana
-
Kenner, Louisiana, États-Unis, 70065
- Ochsner Medical Center Kenner
-
New Orleans, Louisiana, États-Unis, 70121
- Ochsner Medical Center Jefferson
-
-
Maine
-
Augusta, Maine, États-Unis, 04330
- Harold Alfond Center for Cancer Care
-
Bangor, Maine, États-Unis, 04401
- Eastern Maine Medical Center
-
Belfast, Maine, États-Unis, 04915
- MaineHealth Waldo Hospital
-
Biddeford, Maine, États-Unis, 04005
- MaineHealth Maine Medical Center - Biddeford
-
Brewer, Maine, États-Unis, 04412
- Lafayette Family Cancer Center-EMMC
-
Rockport, Maine, États-Unis, 04856
- Penobscot Bay Medical Center
-
Sanford, Maine, États-Unis, 04073
- MaineHealth Cancer Care and IV Therapy - Sanford
-
South Portland, Maine, États-Unis, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Maryland
-
Baltimore, Maryland, États-Unis, 21244
- Kaiser Permanente-Woodlawn Medical Center
-
Easton, Maryland, États-Unis, 21601
- University of Maryland Shore Medical Center at Easton
-
Gaithersburg, Maryland, États-Unis, 20879
- Kaiser Permanente-Gaithersburg Medical Center
-
Largo, Maryland, États-Unis, 20774
- Kaiser Permanente - Largo Medical Center
-
Lutherville, Maryland, États-Unis, 21093
- Kaiser Permanente Lutherville - Timonium Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Dana-Farber Cancer Institute
-
Lowell, Massachusetts, États-Unis, 01854
- Lowell General Hospital
-
-
Michigan
-
Ann Arbor, Michigan, États-Unis, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Bay City, Michigan, États-Unis, 48706
- McLaren Cancer Institute-Bay City
-
Bloomfield, Michigan, États-Unis, 48302
- McLaren Cancer Institute-Bloomfield
-
Brighton, Michigan, États-Unis, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, États-Unis, 48114
- Trinity Health Medical Center - Brighton
-
Brownstown, Michigan, États-Unis, 48183
- Henry Ford Cancer Institute-Downriver
-
Canton, Michigan, États-Unis, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, États-Unis, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, États-Unis, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, États-Unis, 48118
- Chelsea Hospital
-
Clarkston, Michigan, États-Unis, 48346
- McLaren Cancer Institute-Clarkston
-
Clarkston, Michigan, États-Unis, 48346
- Hematology Oncology Consultants-Clarkston
-
Clarkston, Michigan, États-Unis, 48346
- Newland Medical Associates-Clarkston
-
Clinton Township, Michigan, États-Unis, 48038
- Henry Ford Macomb Hospital-Clinton Township
-
Dearborn, Michigan, États-Unis, 48126
- Henry Ford Medical Center-Fairlane
-
Detroit, Michigan, États-Unis, 48202
- Henry Ford Hospital
-
Detroit, Michigan, États-Unis, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, États-Unis, 48334
- Weisberg Cancer Treatment Center
-
Flint, Michigan, États-Unis, 48532
- McLaren Cancer Institute-Flint
-
Flint, Michigan, États-Unis, 48532
- Singh and Arora Hematology Oncology PC
-
Grand Rapids, Michigan, États-Unis, 49503
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Jackson, Michigan, États-Unis, 49201
- Allegiance Health
-
Kalamazoo, Michigan, États-Unis, 49007
- West Michigan Cancer Center
-
Lansing, Michigan, États-Unis, 48910
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Lansing, Michigan, États-Unis, 48912
- University of Michigan Health - Sparrow Lansing
-
Lapeer, Michigan, États-Unis, 48446
- McLaren Cancer Institute-Lapeer Region
-
Livonia, Michigan, États-Unis, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Livonia, Michigan, États-Unis, 48154
- Hope Cancer Clinic
-
Mount Clemens, Michigan, États-Unis, 48043
- McLaren Cancer Institute-Macomb
-
Mount Pleasant, Michigan, États-Unis, 48858
- McLaren Cancer Institute-Central Michigan
-
Novi, Michigan, États-Unis, 48377
- Henry Ford Medical Center-Columbus
-
Petoskey, Michigan, États-Unis, 49770
- McLaren Cancer Institute-Northern Michigan
-
Pontiac, Michigan, États-Unis, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, États-Unis, 48341
- Trinity Health IHA Medical Group-Alice Gustafson Center
-
Port Huron, Michigan, États-Unis, 48060
- McLaren-Port Huron
-
Saginaw, Michigan, États-Unis, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, États-Unis, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, États-Unis, 48764
- MyMichigan Medical Center Tawas
-
Traverse City, Michigan, États-Unis, 49684
- Munson Medical Center
-
West Bloomfield, Michigan, États-Unis, 48322
- Henry Ford West Bloomfield Hospital
-
West Branch, Michigan, États-Unis, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, États-Unis, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Bemidji, Minnesota, États-Unis, 56601
- Sanford Joe Lueken Cancer Center
-
Burnsville, Minnesota, États-Unis, 55337
- Minnesota Oncology - Burnsville
-
Deer River, Minnesota, États-Unis, 56636
- Essentia Health - Deer River Clinic
-
Duluth, Minnesota, États-Unis, 55805
- Essentia Health Cancer Center
-
Hibbing, Minnesota, États-Unis, 55746
- Essentia Health Hibbing Clinic
-
Maplewood, Minnesota, États-Unis, 55109
- Saint John's Hospital - Healtheast
-
Maplewood, Minnesota, États-Unis, 55109
- Minnesota Oncology Hematology PA-Maplewood
-
Minneapolis, Minnesota, États-Unis, 55415
- Hennepin County Medical Center
-
Minneapolis, Minnesota, États-Unis, 55454
- Health Partners Inc
-
Saint Paul, Minnesota, États-Unis, 55101
- Regions Hospital
-
Saint Paul, Minnesota, États-Unis, 55102
- United Hospital
-
Sandstone, Minnesota, États-Unis, 55072
- Essentia Health Sandstone
-
Virginia, Minnesota, États-Unis, 55792
- Essentia Health Virginia Clinic
-
-
Mississippi
-
Grenada, Mississippi, États-Unis, 38901
- Baptist Cancer Center-Grenada
-
New Albany, Mississippi, États-Unis, 38652
- Baptist Memorial Hospital and Cancer Center-Union County
-
Oxford, Mississippi, États-Unis, 38655
- Baptist Memorial Hospital and Cancer Center-Oxford
-
Southhaven, Mississippi, États-Unis, 38671
- Baptist Memorial Hospital and Cancer Center-Desoto
-
-
Missouri
-
Ballwin, Missouri, États-Unis, 63011
- Mercy Oncology and Hematology - Clayton-Clarkson
-
Cape Girardeau, Missouri, États-Unis, 63703
- Saint Francis Medical Center
-
Columbia, Missouri, États-Unis, 65212
- MU Health - University Hospital/Ellis Fischel Cancer Center
-
Joplin, Missouri, États-Unis, 64804
- Freeman Health System
-
Joplin, Missouri, États-Unis, 64804
- Mercy Hospital Joplin
-
Kansas City, Missouri, États-Unis, 64108
- University Health Truman Medical Center
-
St Louis, Missouri, États-Unis, 63109
- Mercy Infusion Center - Chippewa
-
St Louis, Missouri, États-Unis, 63141
- Mercy Hospital Saint Louis
-
-
Montana
-
Anaconda, Montana, États-Unis, 59711
- Community Hospital of Anaconda
-
Billings, Montana, États-Unis, 59101
- Billings Clinic Cancer Center
-
Bozeman, Montana, États-Unis, 59715
- Bozeman Health Deaconess Hospital
-
Great Falls, Montana, États-Unis, 59405
- Great Falls Clinic
-
Great Falls, Montana, États-Unis, 59405
- Benefis Sletten Cancer Institute
-
Helena, Montana, États-Unis, 59601
- Saint Peter's Community Hospital
-
Kalispell, Montana, États-Unis, 59901
- Logan Health Medical Center
-
Missoula, Montana, États-Unis, 59804
- Community Medical Center
-
-
Nebraska
-
Omaha, Nebraska, États-Unis, 68114
- Nebraska Methodist Hospital
-
-
Nevada
-
Las Vegas, Nevada, États-Unis, 89102
- OptumCare Cancer Care at Charleston
-
Las Vegas, Nevada, États-Unis, 89128
- OptumCare Cancer Care at MountainView
-
Las Vegas, Nevada, États-Unis, 89183
- OptumCare Cancer Care at Fort Apache
-
Reno, Nevada, États-Unis, 89502
- Renown Regional Medical Center
-
-
New Hampshire
-
Lebanon, New Hampshire, États-Unis, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Manchester, New Hampshire, États-Unis, 03104
- Dartmouth Cancer Center - Manchester/ DCC Manchester
-
Nashua, New Hampshire, États-Unis, 03063
- Dartmouth Cancer Center - Nashua
-
-
New Jersey
-
Hamilton, New Jersey, États-Unis, 08690
- The Cancer Institute of New Jersey Hamilton
-
Morristown, New Jersey, États-Unis, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, États-Unis, 08903
- Rutgers Cancer Institute of New Jersey
-
Paramus, New Jersey, États-Unis, 07652
- The Valley Hospital - Luckow Pavilion
-
Ridgewood, New Jersey, États-Unis, 07450
- Valley Health System Ridgewood Campus
-
Somerville, New Jersey, États-Unis, 08876
- Robert Wood Johnson University Hospital Somerset
-
Summit, New Jersey, États-Unis, 07902
- Overlook Hospital
-
-
New Mexico
-
Albuquerque, New Mexico, États-Unis, 87106
- University of New Mexico Cancer Center
-
Albuquerque, New Mexico, États-Unis, 87110
- Presbyterian Kaseman Hospital
-
Las Cruces, New Mexico, États-Unis, 88011
- Memorial Medical Center-Las Cruces
-
Rio Rancho, New Mexico, États-Unis, 87124
- Presbyterian Rust Medical Center/Jorgensen Cancer Center
-
-
New York
-
Buffalo, New York, États-Unis, 14263
- Roswell Park Cancer Institute
-
Elmira, New York, États-Unis, 14905
- Arnot Ogden Medical Center/Falck Cancer Center
-
Lake Success, New York, États-Unis, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, États-Unis, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Rochester, New York, États-Unis, 14642
- University of Rochester
-
White Plains, New York, États-Unis, 10601
- Dickstein Cancer Treatment Center
-
-
North Carolina
-
Chapel Hill, North Carolina, États-Unis, 27599
- UNC Lineberger Comprehensive Cancer Center
-
Clinton, North Carolina, États-Unis, 28328
- Southeastern Medical Oncology Center-Clinton
-
Goldsboro, North Carolina, États-Unis, 27534
- Southeastern Medical Oncology Center-Goldsboro
-
Hendersonville, North Carolina, États-Unis, 28791
- Margaret R Pardee Memorial Hospital
-
Jacksonville, North Carolina, États-Unis, 28546
- Southeastern Medical Oncology Center-Jacksonville
-
Kenansville, North Carolina, États-Unis, 28349
- ECU Health Oncology Kenansville
-
Kinston, North Carolina, États-Unis, 28501
- ECU Health Oncology Kinston
-
Pinehurst, North Carolina, États-Unis, 28374
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Richlands, North Carolina, États-Unis, 28574
- ECU Health Oncology Richlands
-
Winston-Salem, North Carolina, États-Unis, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Bismarck, North Dakota, États-Unis, 58501
- Sanford Bismarck Medical Center
-
Fargo, North Dakota, États-Unis, 58122
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, États-Unis, 58122
- Sanford Broadway Medical Center
-
Grand Forks, North Dakota, États-Unis, 58201
- Altru Cancer Center
-
-
Ohio
-
Akron, Ohio, États-Unis, 44307
- Cleveland Clinic Akron General
-
Belpre, Ohio, États-Unis, 45714
- Strecker Cancer Center-Belpre
-
Centerville, Ohio, États-Unis, 45459
- Miami Valley Hospital South
-
Centerville, Ohio, États-Unis, 45459
- Dayton Physicians LLC-Miami Valley South
-
Chillicothe, Ohio, États-Unis, 45601
- Adena Regional Medical Center
-
Cincinnati, Ohio, États-Unis, 45219
- University of Cincinnati Cancer Center-UC Medical Center
-
Cleveland, Ohio, États-Unis, 44111
- Cleveland Clinic Cancer Center/Fairview Hospital
-
Columbus, Ohio, États-Unis, 43214
- Riverside Methodist Hospital
-
Columbus, Ohio, États-Unis, 43210
- Ohio State University Comprehensive Cancer Center
-
Columbus, Ohio, États-Unis, 43219
- The Mark H Zangmeister Center
-
Columbus, Ohio, États-Unis, 43214
- Columbus Oncology and Hematology Associates Inc
-
Columbus, Ohio, États-Unis, 43228
- Doctors Hospital
-
Columbus, Ohio, États-Unis, 43213
- Mount Carmel East Hospital
-
Columbus, Ohio, États-Unis, 43215
- Grant Medical Center
-
Columbus, Ohio, États-Unis, 43222
- Mount Carmel Health Center West
-
Dayton, Ohio, États-Unis, 45409
- Miami Valley Hospital
-
Delaware, Ohio, États-Unis, 43015
- Delaware Health Center-Grady Cancer Center
-
Delaware, Ohio, États-Unis, 43015
- Grady Memorial Hospital
-
Kettering, Ohio, États-Unis, 45409
- Greater Dayton Cancer Center
-
Lancaster, Ohio, États-Unis, 43130
- Fairfield Medical Center
-
Mansfield, Ohio, États-Unis, 44906
- Cleveland Clinic Cancer Center Mansfield
-
Mansfield, Ohio, États-Unis, 44903
- OhioHealth Mansfield Hospital
-
Marietta, Ohio, États-Unis, 45750
- Marietta Memorial Hospital
-
Marion, Ohio, États-Unis, 43302
- OhioHealth Marion General Hospital
-
Mayfield Heights, Ohio, États-Unis, 44124
- Hillcrest Hospital Cancer Center
-
Mount Vernon, Ohio, États-Unis, 43050
- Knox Community Hospital
-
Newark, Ohio, États-Unis, 43055
- Licking Memorial Hospital
-
Portsmouth, Ohio, États-Unis, 45662
- Southern Ohio Medical Center
-
Sandusky, Ohio, États-Unis, 44870
- North Coast Cancer Care
-
Sylvania, Ohio, États-Unis, 43560
- ProMedica Flower Hospital
-
Warrensville Heights, Ohio, États-Unis, 44122
- South Pointe Hospital
-
West Chester, Ohio, États-Unis, 45069
- University of Cincinnati Cancer Center-West Chester
-
Westerville, Ohio, États-Unis, 43081
- Saint Ann's Hospital
-
Zanesville, Ohio, États-Unis, 43701
- Genesis Healthcare System Cancer Care Center
-
-
Oklahoma
-
Lawton, Oklahoma, États-Unis, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, États-Unis, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, États-Unis, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
Tulsa, Oklahoma, États-Unis, 74133
- Cancer Treatment Centers of America
-
-
Oregon
-
Bend, Oregon, États-Unis, 97701
- Saint Charles Health System
-
Clackamas, Oregon, États-Unis, 97015
- Clackamas Radiation Oncology Center
-
Clackamas, Oregon, États-Unis, 97015
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, États-Unis, 97132
- Providence Newberg Medical Center
-
Ontario, Oregon, États-Unis, 97914
- Saint Alphonsus Cancer Care Center-Ontario
-
Oregon City, Oregon, États-Unis, 97045
- Providence Willamette Falls Medical Center
-
Portland, Oregon, États-Unis, 97213
- Providence Portland Medical Center
-
Portland, Oregon, États-Unis, 97225
- Providence Saint Vincent Medical Center
-
-
Pennsylvania
-
Allentown, Pennsylvania, États-Unis, 18103
- Lehigh Valley Hospital-Cedar Crest
-
Allentown, Pennsylvania, États-Unis, 18104
- Saint Luke's Cancer Center - Allentown
-
Bethlehem, Pennsylvania, États-Unis, 18017
- Lehigh Valley Hospital - Muhlenberg
-
Bethlehem, Pennsylvania, États-Unis, 18015
- Saint Luke's University Hospital-Bethlehem Campus
-
Easton, Pennsylvania, États-Unis, 18045
- Saint Luke's Hospital-Anderson Campus
-
Erie, Pennsylvania, États-Unis, 16544
- Saint Vincent Hospital
-
Harrisburg, Pennsylvania, États-Unis, 17109
- UPMC Pinnacle Cancer Center/Community Osteopathic Campus
-
Jefferson Hills, Pennsylvania, États-Unis, 15025
- Jefferson Hospital
-
Monroeville, Pennsylvania, États-Unis, 15146
- Forbes Hospital
-
Natrona Heights, Pennsylvania, États-Unis, 15065
- Allegheny Valley Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15212
- Allegheny General Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15224
- West Penn Hospital
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- UPMC Hillman Cancer Center
-
Quakertown, Pennsylvania, États-Unis, 18951
- Saint Luke's Hospital-Quakertown Campus
-
West Reading, Pennsylvania, États-Unis, 19611
- Reading Hospital
-
Wexford, Pennsylvania, États-Unis, 15090
- Wexford Health and Wellness Pavilion
-
Willow Grove, Pennsylvania, États-Unis, 19090
- Asplundh Cancer Pavilion
-
-
South Carolina
-
Anderson, South Carolina, États-Unis, 29621
- AnMed Health Cancer Center
-
Beaufort, South Carolina, États-Unis, 29902
- Beaufort Memorial Hospital
-
Boiling Springs, South Carolina, États-Unis, 29316
- Prisma Health Cancer Institute - Spartanburg
-
Easley, South Carolina, États-Unis, 29640
- Prisma Health Cancer Institute - Easley
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Cancer Institute - Faris
-
Greenville, South Carolina, États-Unis, 29607
- Saint Francis Cancer Center
-
Greenville, South Carolina, États-Unis, 29615
- Prisma Health Cancer Institute - Eastside
-
Greenville, South Carolina, États-Unis, 29605
- Prisma Health Cancer Institute - Butternut
-
Greenville, South Carolina, États-Unis, 29601
- Saint Francis Hospital
-
Greer, South Carolina, États-Unis, 29650
- Prisma Health Cancer Institute - Greer
-
Seneca, South Carolina, États-Unis, 29672
- Prisma Health Cancer Institute - Seneca
-
Spartanburg, South Carolina, États-Unis, 29303
- Spartanburg Medical Center
-
-
South Dakota
-
Aberdeen, South Dakota, États-Unis, 57401
- Avera Cancer Institute-Aberdeen
-
Sioux Falls, South Dakota, États-Unis, 57105
- Avera Cancer Institute
-
Sioux Falls, South Dakota, États-Unis, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
Sioux Falls, South Dakota, États-Unis, 57104
- Sanford Cancer Center Oncology Clinic
-
-
Tennessee
-
Bristol, Tennessee, États-Unis, 37620
- Bristol Regional Medical Center
-
Collierville, Tennessee, États-Unis, 38017
- Baptist Memorial Hospital and Cancer Center-Collierville
-
Cookeville, Tennessee, États-Unis, 38501
- Cookeville Regional Medical Center
-
Johnson City, Tennessee, États-Unis, 37604
- Wellmont Medical Associates Oncology and Hematology-Johnson City
-
Kingsport, Tennessee, États-Unis, 37660
- Ballad Health Cancer Care - Kingsport
-
Kingsport, Tennessee, États-Unis, 37660
- Wellmont Holston Valley Hospital and Medical Center
-
Memphis, Tennessee, États-Unis, 38120
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Texas
-
Amarillo, Texas, États-Unis, 79106
- The Don and Sybil Harrington Cancer Center
-
Beaumont, Texas, États-Unis, 77701
- Baptist Hospitals of Southeast Texas Cancer Center
-
Conroe, Texas, États-Unis, 77384
- UT MD Anderson - The Woodlands
-
Dallas, Texas, États-Unis, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, États-Unis, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Edinburg, Texas, États-Unis, 78539
- STCC at DHR Health Institute for Research and Development
-
Houston, Texas, États-Unis, 77026-1967
- Lyndon Baines Johnson General Hospital
-
Houston, Texas, États-Unis, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, États-Unis, 77030
- Houston Methodist Hospital
-
Houston, Texas, États-Unis, 77079
- UT MD Anderson - West Houston
-
League City, Texas, États-Unis, 77573
- UT MD Anderson - League City
-
Port Arthur, Texas, États-Unis, 77642
- Baptist Regional Cancer Network-Cancer Center of Southeast Texas
-
Sugar Land, Texas, États-Unis, 77478
- UT MD Anderson - Sugar Land
-
Temple, Texas, États-Unis, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, États-Unis, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Vermont
-
Saint Johnsbury, Vermont, États-Unis, 05819
- Dartmouth Cancer Center - North
-
-
Virginia
-
Bristol, Virginia, États-Unis, 24201
- Ballad Health Cancer Care - Bristol
-
Burke, Virginia, États-Unis, 22015
- Kaiser Permanente-Burke Medical Center
-
Fishersville, Virginia, États-Unis, 22939
- Augusta Health Center for Cancer and Blood Disorders
-
Lynchburg, Virginia, États-Unis, 24501
- Centra Alan B Pearson Regional Cancer Center
-
McLean, Virginia, États-Unis, 22102
- Kaiser Permanente Tysons Corner Medical Center
-
Norton, Virginia, États-Unis, 24273
- Ballad Health Cancer Care - Norton
-
Richmond, Virginia, États-Unis, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, États-Unis, 23229
- Virginia Cancer Institute
-
Richmond, Virginia, États-Unis, 23298
- VCU Massey Comprehensive Cancer Center
-
South Hill, Virginia, États-Unis, 23970
- VCU Community Memorial Health Center
-
Woodbridge, Virginia, États-Unis, 22192
- Kaiser Permanente-Caton Hill Medical Center
-
-
Washington
-
Edmonds, Washington, États-Unis, 98026
- Swedish Cancer Institute-Edmonds
-
Issaquah, Washington, États-Unis, 98029
- Swedish Cancer Institute-Issaquah
-
Port Townsend, Washington, États-Unis, 98368
- Jefferson Healthcare
-
Seattle, Washington, États-Unis, 98122
- Swedish Medical Center-First Hill
-
Spokane, Washington, États-Unis, 99204
- MultiCare Deaconess Cancer and Blood Specialty Center - Downtown
-
Spokane, Washington, États-Unis, 99218
- MultiCare Deaconess Cancer and Blood Specialty Center - North
-
-
West Virginia
-
Charleston, West Virginia, États-Unis, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
Morgantown, West Virginia, États-Unis, 26506
- West Virginia University Healthcare
-
Parkersburg, West Virginia, États-Unis, 26101
- Camden Clark Medical Center
-
-
Wisconsin
-
Antigo, Wisconsin, États-Unis, 54409
- Aspirus Cancer Care-Antigo-Volm Cancer Center
-
Appleton, Wisconsin, États-Unis, 54911
- ThedaCare Regional Cancer Center
-
Appleton, Wisconsin, États-Unis, 54915
- Ascension Northeast Wisconsin-Saint Elizabeth Cancer Center-Appleton
-
Ashland, Wisconsin, États-Unis, 54806
- Duluth Clinic Ashland
-
Brookfield, Wisconsin, États-Unis, 53045
- Ascension Southeast Wisconsin Hospital-Elmbrook Campus-Brookfield
-
Eau Claire, Wisconsin, États-Unis, 54701
- Marshfield Medical Center-EC Cancer Center
-
Franklin, Wisconsin, États-Unis, 53132
- Reiman Cancer Center-Ascension Wisconsin Health Center-Rawson
-
Green Bay, Wisconsin, États-Unis, 54301
- Bellin Memorial Hospital
-
Janesville, Wisconsin, États-Unis, 53548
- Mercyhealth Hospital and Cancer Center - Janesville
-
Johnson Creek, Wisconsin, États-Unis, 53038
- University of Wisconsin Carbone Cancer Center - Johnson Creek
-
La Crosse, Wisconsin, États-Unis, 54601
- Gundersen Lutheran Medical Center
-
Madison, Wisconsin, États-Unis, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Madison, Wisconsin, États-Unis, 53718
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center
-
Marshfield, Wisconsin, États-Unis, 54449
- Marshfield Medical Center-Marshfield
-
Medford, Wisconsin, États-Unis, 54451
- Aspirus Medford Hospital
-
Minocqua, Wisconsin, États-Unis, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, États-Unis, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, États-Unis, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, États-Unis, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Oshkosh, Wisconsin, États-Unis, 54904
- Ascension Northeast Wisconsin-Mercy Hospital-Oshkosh
-
Racine, Wisconsin, États-Unis, 53405
- Ascension All Saints Hospital-Spring Street-Racine
-
Rhinelander, Wisconsin, États-Unis, 54501
- Aspirus Cancer Care-Rhinelander-James Beck Cancer Center
-
Rice Lake, Wisconsin, États-Unis, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, États-Unis, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, États-Unis, 53188
- UW Cancer Center at ProHealth Care
-
Waukesha, Wisconsin, États-Unis, 53188
- ProHealth Waukesha Memorial Hospital
-
Wausau, Wisconsin, États-Unis, 54401
- Aspirus Cancer Care-Wausau
-
Wauwatosa, Wisconsin, États-Unis, 53226
- Ascension Southeast Wisconsin Hospital-Mayfair Road-Wauwatosa
-
Weston, Wisconsin, États-Unis, 54476
- Marshfield Medical Center - Weston
-
Wisconsin Rapids, Wisconsin, États-Unis, 54494
- Aspirus Cancer Care - Wisconsin Rapids
-
-
Wyoming
-
Cheyenne, Wyoming, États-Unis, 82001
- Cheyenne Regional Medical Center-West
-
Cody, Wyoming, États-Unis, 82414
- Billings Clinic-Cody
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
-
The patient must have signed and dated an Institutional Review Board (IRB)-approved consent form that conforms to federal and institutional guidelines
-
Age >= 18 years
-
Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
-
Diagnosis of metastatic adenocarcinoma of colon or rectum without previous chemotherapy or any other systemic therapy for metastatic colorectal cancer except for one cycle of FOLFOX or capecitabine and oxaliplatin (CAPOX), either with or without bevacizumab prior to enrollment. Upon enrollment, the preceding single cycle of FOLFOX or FOLFOX + bevacizumab, if the patient received one, will not count towards patients' assessments per protocol. Cycle 1 day 1 (C1D1) of atezolizumab or C1D1 of mFOLFOX6/bevacizumab + atezolizumab will correspond to the first day the patient received therapy on trial
-
Tumor determined to be mismatch-repair deficient (dMMR) by Clinical Laboratory Improvement Act (CLIA)-certified immunohistochemical (IHC) assay with a panel of all four IHC markers, including MLH1, MSH2, PMS2, and MSH6; alternatively, MSI-H diagnosed by polymerase chain reaction (PCR)-based assessment of microsatellite alterations (either Bethesda markers or Pentaplex panel) or by next-generation sequencing (NGS) are eligible
-
Documentation by PET/CT scan, CT scan, or MRI that the patient has measurable metastatic disease per RECIST 1.1
-
No immediate need for surgical intervention for the primary tumor or palliative diversion/bypass
-
Absolute neutrophil count (ANC) must be >= 1500/mm^3 (obtained within 28 days prior randomization)
-
Platelet count must be >= 100,000/mm^3 (obtained within 28 days prior randomization)
-
Hemoglobin must be >= 8 g/dL (obtained within 28 days prior randomization)
-
Total bilirubin must be =< 4 x ULN (upper limit of normal) (obtained within 28 days prior randomization); and
-
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN (obtained within 28 days prior randomization)
-
Calculated creatinine clearance >= 30 mL/min (obtained within 28 days prior randomization)
-
A urine sample tested for proteinuria by either the dipstick method, urinalysis (UA), or a urine protein creatinine (UPC) ratio:
- The dipstick method must indicate 0-1+ protein; if dipstick reading is >= 2+, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
- A urine protein creatinine (UPC) ratio must be < 1.0; if the UPC ratio is >= 1.0 a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours
- Urinalysis must indicate < 30 mg/dl. If urinalysis >= 30 mg/dl, a 24-hour urine must be done and it must demonstrate < 1.0 g of protein per 24 hours or a UPC ratio < 1.0
-
International normalized ratio of prothrombin time (INR) and prothrombin time (PT) must be =< 1.5 x ULN for the lab within 28 days before randomization; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical history, regardless of PT/INR results
-
Pregnancy test done within 28 days prior randomization must be negative (for women of childbearing potential only); pregnancy testing should be performed according to institutional standards; administration of atezolizumab or mFOLFOX6/bevacizumab/atezolizumab may have an adverse effect on pregnancy and poses a risk to the human fetus, including embryo-lethality; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
-
Women of child-bearing potential and men must agree to use adequate contraception methods that result in a failure rate of < 1% per year during the treatment period (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 5 months (150 days) after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, and 6 months after the last dose of mFOLFOX6; a woman is considered to be of childbearing potential if she is not postmenopausal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus); examples of contraceptive methods with a failure rate of < 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices; the reliability of sexual abstinence should be evaluated in relation to the duration of the clinical study and the preferred and usual lifestyle of the patient; periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception; men must refrain from donating sperm during this same period
Exclusion Criteria:
-
Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies, fluoropyrimidines, folic acid derivatives or oxaliplatin
-
Uncontrolled high blood pressure defined as systolic blood pressure (BP) > 150 mmHg or diastolic BP > 100 mmHg with or without anti-hypertensive medication; patients with initial BP elevations are eligible if initiation or adjustment of BP medication lowers pressure to meet entry criteria
-
Documented New York Heart Association (NYHA) class III or IV congestive heart failure
-
Serious or non-healing wound, skin ulcer, or bone fracture
-
History of inherited bleeding diathesis, gastrointestinal (GI) perforation, significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis or symptomatic peripheral ischemia, transient ischemic attack [TIA], cerebrovascular accident [CVA] or arterial thrombotic event), abdominal fistula, intra-abdominal abscess, or active GI bleeding (with cause not addressed) within 6 months prior to randomization, or other medical condition in the opinion of the treating oncologist that makes the risk of cardiovascular or bleeding complications with bevacizumab use unacceptably high
-
Other malignancies are excluded unless the patient has completed therapy for the malignancy >= 12 months prior to randomization and is considered disease-free; patients with the following cancers are eligible if diagnosed and treated within the past 12 months: in situ carcinomas or basal cell and squamous cell carcinoma of the skin
-
Known DPD (dihydro pyrimidine dehydrogenase) deficiency
-
Symptomatic peripheral sensory neuropathy >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] version [v] 5.0)
-
Prior treatment with oxaliplatin chemotherapy within 6 months prior to randomization
-
History of grade 2 hemoptysis (defined as 2.5 mL of bright red blood per episode) within 1 month prior to screening
-
Prior treatment with anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents; patients who have received prior treatment with anti-CTLA-4 may be enrolled provided the following requirements are met:
- Minimum of 12 weeks from the first dose of anti-CTLA-4 and > 6 weeks from the last dose to randomization
- No history of severe immune-related adverse effects (CTCAE grade 3 and 4) from anti-CTLA-4
-
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization; however,
- Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea; or chronic daily treatment with corticosteroids with a dose of =< 10 mg/day methylprednisolone equivalent) may be enrolled
- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed
-
Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease; however,
- Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HbsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible if polymerase chain reaction (PCR) for hepatits B virus (HBV) ribonucleic acid (RNA) is negative per local guidelines
- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA per local guidelines
-
History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis; however,
-
Patients with a history of autoimmune hypothyroidism on a stable dose of thyroid replacement hormone may be eligible
-
Patients with controlled type 1 diabetes mellitus on a stable insulin regimen may be eligible
-
Patients with eczema, psoriasis, lichen simplex chronicus or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:
- Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations
- Rash must cover less than 10% of body surface area (BSA)
- Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, fluocinolone 0.01%, desonide 0.05%, alclometasone dipropionate 0.05%)
- No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation [PUVA], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)
-
-
History of idiopathic pulmonary fibrosis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or active or recently active (within 90 days of randomization) pneumonitis (including drug induced) that required systemic immunosuppressive therapy (i.e. corticosteroids, etc.). History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
-
Patients with known active tuberculosis (TB) are excluded
-
Severe infections within 28 days prior to randomization, including but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia
-
Signs or symptoms of infection within 14 days prior to randomization
-
Received oral or intravenous (IV) antibiotics within 14 days prior to randomization; patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are eligible
-
Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to randomization or anticipation of need for a major surgical procedure during the course of the study
-
The administration of a live, attenuated vaccine within 28 days prior to randomization
-
Pregnant women are excluded from this study because atezolizumab is an agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with atezolizumab, breastfeeding should be discontinued if the mother is treated with atezolizumab; these potential risks may also apply to other agents used in this study; (Note: pregnancy testing should be performed within 28 days prior to randomization according to institutional standards for women of childbearing potential)
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
Patients with prior allogeneic bone marrow transplantation or prior solid organ transplantation
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Arm I (bevacizumab, mFOLFOX6)
Patients receive bevacizumab intravenously (IV) over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 of cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on days 1 and 2. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. (CLOSED TO ACCRUAL) |
Ancillary studies
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo MRI
Autres noms:
Ancillary studies Undergo collection of blood samples
Autres noms:
Given IV
Autres noms:
Undergo CT or CT/PET
Autres noms:
Given IV
Autres noms:
Undergo CT/PET
Autres noms:
|
|
Expérimental: Arm II (atezolizumab)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Autres noms:
Undergo MRI
Autres noms:
Ancillary studies Undergo collection of blood samples
Autres noms:
Given IV
Autres noms:
Undergo CT or CT/PET
Autres noms:
Undergo CT/PET
Autres noms:
|
|
Expérimental: Arm III (atezolizumab, bevacizumab, mFOLFOX6)
Patients receive atezolizumab IV over 30-60 minutes on day 1. Treatment repeats every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive bevacizumab IV over 30-90 minutes on day 1, oxaliplatin IV over 2 hours on day 1 cycles 1-10, leucovorin calcium IV over 2 hours on day 1, and fluorouracil IV over 46-48 hours on day 1. Treatment with oxaliplatin repeats every 2 weeks for up to 10 cycles in the absence of disease progression or unacceptable toxicity. Treatment of bevacizumab, leucovorin calcium, and fluorouracil repeat every 2 weeks for up to 48 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with or without PET or MRI throughout the trial. Patients may also undergo collection of optional blood samples throughout the trial. |
Ancillary studies
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo MRI
Autres noms:
Ancillary studies Undergo collection of blood samples
Autres noms:
Given IV
Autres noms:
Given IV
Autres noms:
Undergo CT or CT/PET
Autres noms:
Given IV
Autres noms:
Undergo CT/PET
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression free survival (PFS)
Délai: From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
The analysis set is intent-to-treat (ITT). The experimental arms will be compared to the control arm by the log-rank test stratified by BRAF status (V600E mutation or not), metastatic disease: (liver-only, extra-hepatic), and prior adjuvant therapy for colon cancer (yes, no). Hazard ratios and associated confidence intervals from a stratified Cox regression model will also be reported along with estimates of the distributions of time to PFS event by the method of Kaplan and Meier. Sensitivity analyses accounting for 2 or more consecutively missed scheduled tumor imaging scans before progression/death will also be conducted. |
From the time from randomization until first confirmed progression or death from any cause, assessed up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Taux de SSP
Délai: A 12 mois
|
A 12 mois
|
|
|
Overall survival (OS)
Délai: The time from randomization to death from any cause, assessed up to 5 years
|
Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
The time from randomization to death from any cause, assessed up to 5 years
|
|
Objective response rate (ORR) (complete response [CR] or partial response [PR])
Délai: Up to 5 years
|
Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemotherapy [chemo]) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
Up to 5 years
|
|
Incidence of adverse events
Délai: Up to 30 days after last cycle
|
Defined by Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The safety profile will be described by tabulating the maximum observed grade of adverse event for each individual adverse event, for each system organ class, and overall using the Safety population. |
Up to 30 days after last cycle
|
|
Disease control rate (CR + PR + stable disease [SD])
Délai: At 12 months
|
Assessed by RECIST 1.1. Will be analyzed by a logistic regression models that control for the stratification factors (BRAF status, liver involvement, and adjuvant chemo) using the ITT population. Observed proportions along with confidence intervals will be presented by treatment. |
At 12 months
|
|
Duration of overall response (CR or PR)
Délai: From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed by RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first response to first confirmed progression by the study investigator or death from any cause, assessed up to 5 years
|
|
Duration of SD
Délai: From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Assessed per RECIST 1.1. Will be analyzed using the stratified log rank test and the ITT population. Kaplan-Meier plots will illustrate the distribution of these endpoints by treatment. Stratified Cox regression models will be used to estimate hazard ratios and associated confidence intervals. |
From the time of first on-study assessment of SD to first progression by the study investigator or death from any cause, assessed up to 5 years
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Severity of fatigue
Délai: At 16 weeks
|
Will use the ITT population. Measured by the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue questionnaire. Will be compared between the control arm (Chemo-bevacizumab [Bev]) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Physical functioning
Délai: At 16 weeks
|
Will use the ITT population. Measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life questionnaire (QLQ)-C30 physical functioning scale. Will be compared between the control arm (Chemo-Bev) and the experimental arm by means of ordinal logistic regression with adjustment for the corresponding baseline measurement and stratification variables. The comparison will be performed at the significance level of 0.05 (two-sided) and the clinical meaningfulness of the comparison will be considered. |
At 16 weeks
|
|
Health utility scores
Délai: Up to 5 years
|
Will use the ITT population. Will be measured using the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) questionnaire. |
Up to 5 years
|
|
Proportion of patients reporting each response option at each assessment timepoint by treatment arm for item GP5 from the Functional Assessment of Cancer Therapy - General (FACT-G)
Délai: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Intratumoral lymphocyte PD-L1+ expression (>= 1 % is positive) by immunohistochemistry (IHC) as a predictive biomarker of efficacy
Délai: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy dependent on the number of somatic mutations
Délai: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Efficacy in tumors with MLH1 silencing
Délai: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Change in quantification of cell free deoxyribonucleic acid (cfDNA) mutations
Délai: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
Development of progression or relapse to treatment in cfDNA
Délai: Up to 5 years
|
Will use the ITT population. |
Up to 5 years
|
|
Changes in T-cell repertoire diversity as a predictive biomarker of efficacy
Délai: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
|
PFS of patients with high levels of diversity
Délai: Up to 5 years
|
Compared to patients with low levels of diversity. Will use the ITT population. |
Up to 5 years
|
|
Change in T-cell diversity
Délai: Baseline to first restaging between immunotherapy arms and the standard of care arm
|
Will use the ITT population. |
Baseline to first restaging between immunotherapy arms and the standard of care arm
|
|
Mechanism of immune resistance to PD-1 blockade in mismatch repair deficient (dMMR)/microsatellite instability-high metastatic colorectal cancer (mCRC) by comparative analysis of tumor samples collected
Délai: Baseline up to 5 years
|
Will use the ITT population. |
Baseline up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Caio Max S Rocha Lima, NRG Oncology
Publications et liens utiles
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimé)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Tumeurs par site
- Tumeurs
- Maladies intestinales
- Tumeurs gastro-intestinales
- Tumeurs du système digestif
- Maladies du système digestif
- Maladies gastro-intestinales
- Tumeurs intestinales
- Maladies rectales
- Maladies du côlon
- Tumeurs colorectales
- Acides aminés, peptides et protéines
- Protéines
- Composés de soufre
- Produits chimiques organiques
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Techniques d'investigation
- Techniques de laboratoire clinique
- Techniques et procédures de diagnostic
- Diagnostic
- Enzymes et coenzymes
- Anticorps, monoclonal, humanisé
- Anticorps, monoclonal
- Anticorps
- Immunoglobulines
- Immunoprotéines
- Protéines sanguines
- Globulines sériques
- Globulines
- Produits chimiques inorganiques
- Complexes de coordination
- Pyrimidines
- Techniques de chimie, analytique
- Analyse du spectre
- Formyltétrahydrofolate
- Tétrahydrofolat
- Acide folique
- Pterines
- Ptéridines
- Uracile
- Pyrimidinones
- Coenzymes
- Isotypes d'immunoglobulines
- Sulfures
- Anions
- Ions
- Électrolytes
- Sulfure d'hydrogène
- Oxaliplatine
- Bévacizumab
- Fluorouracile
- Leucovorine
- Immunoglobuline G
- Manipulation des échantillons
- Spectroscopie de résonance magnétique
- Disulfures
- atézolizumab
- déshydroftorafur
Autres numéros d'identification d'étude
- NCI-2016-01961
- U10CA180868 (Subvention/contrat des NIH des États-Unis)
- NCI-2016-01961 (Identificateur de registre: CTRP (Clinical Trial Reporting Program))
- NRG-GI004/S1610
- NRG-GI004 (Autre identifiant: CTEP)
- NRG-GI004 (Autre identifiant: NRG Oncology)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .